Proceedings of the ISPD 2006 The 11th Congress of the ISPD /07 $

Size: px
Start display at page:

Download "Proceedings of the ISPD 2006 The 11th Congress of the ISPD /07 $"

Transcription

1 Proceedings of the ISPD 2006 The 11th Congress of the ISPD /07 $ August 25 29, 2006, Hong Kong Copyright 2007 International Society for Peritoneal Dialysis Peritoneal Dialysis International, Vol. 27 (2007), Supplement 2 Printed in Canada. All rights reserved. CARDIOVASCULAR RISK FACTORS IN PERITONEAL DIALYSIS PATIENTS REVISITED Angela Yee-Moon Wang University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, PR China End-stage renal disease patients are at a heightened risk of developing cardiovascular disease, with contributions from both traditional and nontraditional cardiovascular risk factors. Some of the nontraditional risk factors, such as extracellular volume overload, inflammation, and hyperphosphatemia, have also been shown to be important predictors of mortality in the dialysis population. This article provides an in-depth review of the evidence that supports the substantial contributions of nontraditional risk factors to adverse cardiovascular outcomes in chronic peritoneal dialysis patients. In addition, it provides evidence to demonstrate how loss of residual renal function may be central to the development of cardiovascular disease in the peritoneal dialysis population. Perit Dial Int 2007; 27(S2):S223 S227 KEY WORDS: Cardiovascular; residual renal function; inflammation; calcification; cardiac hypertrophy. According to the U.S. Renal Data System and the European Renal Association European Dialysis and Transplantation Association registry (1), mortality among end-stage renal disease (ESRD) patients is at least 10 to 20 times that of an age-, race-, and sex-matched general population. Moreover, at least half of all deaths in ESRD patients are attributable to cardiovascular causes. These facts are in keeping with data from the Hong Kong renal registry, which show that more than 50% of the mortality in chronic peritoneal dialysis (PD) patients is attributable to cardiovascular disease. Although a greater prevalence of traditional Framingham risk factors such as hypertension, high blood cholesterol, and diabetes have been observed in chronic kidney disease patients and in patients on dialysis as compared with patients having normal kidney function Correspondence to: A.Y.M. Wang, University Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, PR China. (2), evidence is accumulating that a whole host of nontraditional risk factors or, more correctly, kidney disease-related risk factors, including chronic inflammation, deranged calcium phosphorus metabolism, extracellular volume overload, anemia, increased oxidative stress, hyperparathyroidism, hyperhomocysteinemia, insulin resistance, and sympathetic overactivity also predispose those patients to an increased risk of cardiovascular events and mortality. This article reviews some of these highly prevalent cardiovascular risk factors that have been shown to predict cardiovascular outcome in PD patients. EXTRACELLULAR VOLUME OVERLOAD Chronic PD patients frequently exhibit the complication of extracellular volume overload. According to a study by Tzamaloukas et al. (3), symptomatic volume overload may manifest in various ways, including peripheral edema (100% of patients), pulmonary congestion (80%), pleural effusion (76%), systolic hypertension (83%), and diastolic hypertension (66%). A recent study showed that close to 40% of chronic PD patients developed one or more episodes of circulatory congestion during a 3-year prospective follow-up (4). The causes of extracellular volume overload are usually multifactorial, including noncompliance with fluid intake restrictions, low effluent drain volumes, and high membrane transport status. Diabetes is also associated with increased risk of extracellular volume overload (3). As shown by Ates et al. (5), the degree of sodium and fluid removal significantly influences the survival of PD patients, in that patients with lower sodium and fluid removal have a higher mortality rate that may be attributable to extracellular volume overload with resulting greater left ventricular (LV) hypertrophy and dysfunction. That finding is in keeping with a study that showed more severe LV hypertrophy, dilatation, and ventricular dysfunction among patients with a previous history of S223

2 PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD JUNE 2007 VOL. 27, SUPPL 2 PDI volume overload than in those with no such previous history (6). The foregoing observations raise two possibilities. First, as compared with patients having with no previous history of volume overload, patients with such a history may remain persistently volume overloaded. Second, an episode of volume overload, though now in the past and presumably resolved, may continue to exert negative effects on the myocardium, resulting in more severe LV hypertrophy. In chronic PD patients, LV hypertrophy is an important predictor of mortality and cardiovascular death (7). A previous study showed that more than 90% of prevalent PD patients have LV hypertrophy (7). The presence of congestive heart failure also predicts mortality in patients on dialysis (8). Furthermore, progression of LV hypertrophy provides important prognostic information (9). Controlling for baseline LV mass index and other clinical and demographic factors, patients with a >75th percentile increase in LV mass over a mean interval of 18 ± 2 months (standard deviation) had a mortality and cardiovascular event risk that was 3 times that of patients having minimal increases in LV mass. Thus, achieving strict volume control appears to be an important therapeutic strategy for inducing regression of LV hypertrophy and lowering cardiovascular event risk in chronic PD patients. On the other hand, extracellular volume overload in PD patients may be partly attributable to decline of residual renal function (RRF), which itself is an important predictor of mortality (10). Long-term continuous ambulatory PD (CAPD) has been suggested to be disadvantageous in preserving cardiac performance (11). Evidence also suggests that long-term CAPD patients show greater volume expansion and LV hypertrophy than hemodialysis patients do (12). In the reanalysis of data from the CANUSA study (13), RRF was shown to be a more important contributor to the overall survival of PD patients than PD clearance was. The importance of RRF in PD patients appears to be mediated partly by its influence on fluid removal: entering urine volume into the Cox regression model for mortality completely displaces residual glomerular filtration rate (GFR) from the model. That finding accords well with a study showing that volume expansion in PD patients is related not only to peritoneal transport characteristics but also to residual GFR (14). Taken together with the previous demonstration of the novel association between residual GFR and LV hypertrophy (15), this suggests that RRF may play an important role in extracellular volume control and that extracellular volume overload may in part explain the link between loss of RRF and development of LV hypertrophy in PD patients. S224 INFLAMMATION Dialysis patients are at an increased risk of accelerated atherosclerosis partly because of the presence of inflammation. The prototypic markers of inflammation, C-reactive protein (CRP) and interleukin-6 (IL-6), have been shown to play a role in atherosclerosis (16,17). Previous studies have demonstrated the importance of inflammation, as denoted by CRP, in predicting mortality and cardiovascular death in PD and hemodialysis patients (18). More recently, CRP was shown to predict the time to occurrence of cardiac events in dialysis patients (19). The causes of inflammation in PD patients are usually multifactorial: infections, malnutrition, bioincompatible dialysis solution, and cardiovascular disease (20). Of note is the important inverse relationship observed between inflammation and RRF in PD patients (10). Anuric PD patients had higher serum levels of CRP than did patients with preserved RRF (21). In addition, CRP was positively linked with arterial stiffening, as denoted by arterial pulse pressure, LV hypertrophy, dilatation, and systolic dysfunction (7). Although the exact relationships between inflammation, RRF, and LV hypertrophy have yet to be determined, the previous study clearly demonstrated that inflammation, loss of RRF, and LV hypertrophy combined adversely to heighten risk of mortality and cardiovascular death in PD patients (7). Vascular cell adhesion molecule 1 (VCAM-1) is involved in leukocyte endothelial cell interactions and plays a pivotal role in inflammation. In PD patients, a strong inverse relationship was recently observed between RRF and circulating soluble VCAM-1 (22). In addition, there is evidence that the association between loss of RRF and increased mortality and cardiovascular events in PD patients may be partly mediated by an increased inflammatory profile as evidenced by elevated levels of the adhesion molecule in the circulation. Data also suggest that IL-6 may serve as a better inflammatory biomarker than CRP in predicting mortality and cardiovascular outcomes in ESRD patients (23 25). Tripepi et al. showed that, in ESRD patients, IL-6 adds significant predictive power to estimates of mortality and cardiovascular death risk (26). In another study, Honda et al. found that, in comparison with other inflammatory markers including serum albumin, high-sensitivity CRP, and fetuin-a, IL-6 had the highest predictive value for cardiovascular disease and clinical outcome in ESRD patients (27). The importance of IL-6 in mediating cardiovascular disease is further reinforced by a recent study showing that functional variants of the IL-6 gene ( 174C carriers in the absence of 162 Val allele) affect inflammation and risk of cardiovascular disease in dialysis patients (28).

3 PDI JUNE 2007 VOL. 27, SUPPL 2 PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD HYPERPHOSPHATEMIA Hyperphosphatemia and increased Ca P product are well-established risk factors for mortality and cardiovascular death in hemodialysis patients and PD patients alike (29,30). They also contribute to an increased risk of vascular, valvular, and other tissue calcification. Although hyperphosphatemia was once considered to be a relatively infrequent complication in PD patients, increasing evidence suggests that it is highly prevalent in the PD population. The Netherlands Cooperative Study on the Adequacy of Dialysis and a study by Wang et al. (30,31) both showed that about 40% of chronic PD patients have a serum phosphorus level above the target 1.78 mmol/l recommended by the Kidney Disease Outcomes Quality Initiative. Among patients with preserved RRF, residual GFR was second to dietary protein intake in the list of the most important factors associated with hyperphosphatemia. Residual GFR was even more important than PD clearance. However, among anuric patients, the adequacy of PD clearance appeared to be the most important determinant of serum phosphorus control (31). Based on the data, it appears that total weekly urea and creatinine clearances of at least 2.0 and 60 L/1.73 m 2 respectively may be optimal targets for maintaining serum phosphorus below 5 mg/dl in Chinese CAPD patients. However, the data also suggest the inadequacy of PD alone in achieving adequate phosphorus control in anuric PD patients. One major clinical consequence of hyperphosphatemia is the development of vascular, valvular, and other tissue calcification. The importance of vascular calcification in predicting mortality and cardiovascular death has been demonstrated in hemodialysis patients (32). Valvular calcification is also a powerful predictor of mortality and cardiovascular death in PD patients (33). Vascular calcification in ESRD patients commonly occurs in both the intimal and the medial layers. Vascular calcification secondary to hyperphosphatemia typically occurs in the media and is associated with generalized arterial stiffening that increases the afterload and results in LV hypertrophy (34,35), which may reduce coronary flow reserve and increase risk of myocardial ischemia. Further, data from animal studies show that hyperphosphatemia may increase cardiac fibrosis and hypertrophy, and aggravate microvascular disease (36). On the other hand, vascular calcification occurring in the intimal layer is typically atherosclerotic in nature and may lead to obstructive coronary lesions with resulting coronary ischemia. Interestingly, previous data suggest that valvular calcification also represents a marker of atherosclerosis in PD patients, as evidenced by its association with greater carotid intima media thickness and more plaque calcification (37). The prevalence of coronary artery calcification (CAC) was reported to range from 40% to 100% in the dialysis population (38 41). To date, most of those surveys were conducted in hemodialysis populations, and only a few surveys in PD populations are available. In one of the latter surveys, the prevalence of CAC was reported to be 60% (42). Using echocardiography, one third of the Chinese PD population were noted to have valvular calcification. In addition, a much higher CAC score was observed in dialysis patients than in age- and sex-matched non-dialysis control subjects with coronary artery disease (38). In dialysis patients, CAC is rapidly progressive (41). In a recent longitudinal study that included PD patients only, serum phosphorus and Ca P product were found to be the most important factors predicting progression of CAC (43). Other factors that may predispose to cardiac calcification include increasing age, increasing dialysis duration, and cumulative dose of calcium-based binders (41). The use of calcium-based binders was most likely to be associated with progressive CAC when mineral metabolism was not well controlled (44). That finding is in keeping with a study showing that sevelamer hydrochloride, a non-calcium-based binder, attenuates the progression of CAC in hemodialysis patients (45). Evidence that inflammation may be involved in the calcification process is also increasing, as shown by the important link between inflammation and valvular calcification (46). Reduced circulating levels of the calcification inhibitor fetuin-a, which is a negative acute-phase reactant, predicts mortality in dialysis patients (47) and is also associated with increased risk of valvular calcification (48). The recent finding that higher CRP is associated with more rapid annualized progression of CAC score in dialysis patients is further evidence to support the role of inflammation in mediating calcification (49). On the other hand, a recent unpublished observation by Wang and colleagues suggests that loss of RRF also predisposes PD patients to an increased risk of valvular calcification as a result of higher Ca P product and increased inflammation. Of additional importance is the observation that inflammation, high Ca P product, loss of RRF, and valvular calcification combine adversely to increase the severity of LV hypertrophy in PD patients. CONCLUSIONS Patients on PD are at a heightened risk of developing accelerated atherosclerosis, vascular and valvular calcification, and LV hypertrophy secondary to a S225

4 PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD JUNE 2007 VOL. 27, SUPPL 2 PDI multitude of traditional and kidney disease related risk factors. Previous studies suggest that the prevalence and severity of some of these risk factors may increase with decline in RRF. More attention should be paid to preserving RRF and improving cardiovascular outcomes in PD patients. ACKNOWLEDGMENT The work described here is supported by funds from the Hong Kong Health Service Research Grant, Hong Kong Society of Nephrology Research Grants, and the Baxter Extramural Grant Program. REFERENCES 1. Raine AE, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P, et al. Report on management of renal failure in Europe, XXII, Nephrol Dial Transplant 1992; 7(Suppl 2): Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13: Tzamaloukas AH, Saddler MC, Murata GH, Malhotra D, Sena P, Simon D, et al. Symptomatic fluid retention in patients on continuous peritoneal dialysis. J Am Soc Nephrol 1995; 6: Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Lui SF, et al. Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. Kidney Int 2006; 70: Ates K, Nergizoglu G, Keven K, Sen A, Kutlay S, Erturk S, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60: Wang AY, Sanderson J, Sea MM, Wang M, Lam CW, Li PK, et al. Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. Am J Clin Nutr 2003; 77: Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15: Harnett JD, Foley RN, Kent GM, Barré PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65: S Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14: Takeda K, Nakamoto M, Hirakata H, Baba M, Kubo M, Fujishima M. Disadvantage of long-term CAPD for preserving cardiac performance: an echocardiographic study. Am J Kidney Dis 1998; 32: Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001; 16: Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: Konings CJ, Kooman JP, Schonck M, Struijk DG, Gladziwa U, Hoorntje SJ, et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 2003; 18: Wang AY, Wang M, Woo J, Law MC, Chow KM, Li PK, et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62: Libby P. Inflammation in atherosclerosis. Nature 2002; 420: Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-Reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003; 21: Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: Hase H, Joki N, Ishikawa H, Saijyo T, Tanaka Y, Takahashi Y, et al. Independent risk factors for progression of coronary atherosclerosis in hemodialysis patients. Ther Apher Dial 2006; 10: Wang AY. Prognostic value of C-reactive protein for heart disease in dialysis patients. Curr Opin Investig Drugs 2005; 6: Wang AY, Woo J, Wang M, Sea MM, Sanderson JE, Lui SF, et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005; 20: Wang AY, Lam CW, Wang M, Woo J, Chan IH, Lui SF, et al. Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis 2005; 45: Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein

5 PDI JUNE 2007 VOL. 27, SUPPL 2 PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD in haemodialysis patients. Nephrol Dial Transplant 2004; 19: Pecoits Filho R, Bárány P, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005; 45: Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16(Suppl 1):S Honda H, Qureshi AR, Heimbürger O, Bárány P, Wang K, Pecoits Filho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: Liu Y, Berthier Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 2006; 17: Block GA, Hulbert Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: Noordzij M, Korevaar JC, Bos WJ, Boeschoten EW, Dekker FW, Bossuyt PM, et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 2006; 21: Wang AY, Woo J, Sea MM, Law MC, Lui SF, Li PK. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications? Am J Kidney Dis 2004; 43: Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an important predictor for allcause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14: Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004; 65: London GM, Marchais SJ, Guerin AP, Metivier F, Adda H. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17: Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, El- Shakmak A, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003; 63: Wang AY, Ho SS, Wang M, Liu EK, Ho S, Li PK, et al. Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease. Arch Intern Med 2005; 165: Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: Raggi P, Boulay A, Chasan Taber S, Amin N, Dillon M, Burke SK, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: Moe SM, O Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P, et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 2003; 18: Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: Stompor T, Pasowicz M, Sullowicz W, Dembinska Kiec A, Janda K, Wojcik K, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003; 41: Stompor TP, Pasowicz M, Sulowicz W, Dembinska Kiec A, Janda K, Wojcik K, et al. Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am J Kidney Dis 2004; 44: Chertow GM, Raggi P, Chasan Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: Wang AY, Woo J, Wang M, Sea MM, Ip R, Li PK, et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001; 12: Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-a (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, et al. Associations of serum fetuin-a with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006; 21: S227

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate

More information

In hemodialysis (HD), the conventional practice for

In hemodialysis (HD), the conventional practice for VIIth International Course on Peritoneal Dialysis May 23 26, 2000, Vicenza, Italy Peritoneal Dialysis International, Vol. 20, Suppl. 2 0896-8608/00 $3.00 +.00 Copyright 2000 International Society for Peritoneal

More information

Peritoneal Dialysis Adequacy. Suzanne Watnick, MD Associate Professor of Medicine Training Program Director Oregon Health & Science University

Peritoneal Dialysis Adequacy. Suzanne Watnick, MD Associate Professor of Medicine Training Program Director Oregon Health & Science University Peritoneal Dialysis Adequacy Suzanne Watnick, MD Associate Professor of Medicine Training Program Director Oregon Health & Science University Outline of Talk What is Adequacy (Definition)? What do the

More information

Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, 2011 - ESRD Registry Committee, Korean Society of Nephrology*

Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, 2011 - ESRD Registry Committee, Korean Society of Nephrology* Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, 2011 - ESRD Registry Committee, Korean Society of Nephrology* =Abstracts= Registry committee of Korean Society of Nephrology

More information

NUTRITIONAL REQUIREMENTS OF PERITONEAL DIALYSIS. J. Kevin Tucker, M.D. Brigham and Women s Hospital Massachusetts General Hospital

NUTRITIONAL REQUIREMENTS OF PERITONEAL DIALYSIS. J. Kevin Tucker, M.D. Brigham and Women s Hospital Massachusetts General Hospital NUTRITIONAL REQUIREMENTS OF PERITONEAL DIALYSIS J. Kevin Tucker, M.D. Brigham and Women s Hospital Massachusetts General Hospital Outline Prevalence of protein-energy wasting in peritoneal dialysis Nutritional

More information

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized

More information

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University

More information

Importance of UF and Clinical Management in PD

Importance of UF and Clinical Management in PD Importance of UF and Clinical Management in PD Ali K. Abu-Alfa, MD, FASN Professor of Medicine Head, Division of Nephrology and Hypertension American University of Beirut Beirut, Lebanon Adjunct Faculty

More information

The sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C:

The sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C: The sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C: The good correlation allows close estimation of GFR Cystatin C GFR GFR in serum estimated* measured* n

More information

Elderly Diabetic Patients on Peritoneal Dialysis

Elderly Diabetic Patients on Peritoneal Dialysis Advances in Peritoneal Dialysis, Vol. 25, 2009 Ploumis Passadakis, 1 Dimitrios G. Oreopoulos 2 Elderly Diabetic Patients on Peritoneal Dialysis Diabetes mellitus is the fastest-growing cause of end-stage

More information

25-hydroxyvitamin D: from bone and mineral to general health marker

25-hydroxyvitamin D: from bone and mineral to general health marker DIABETES 25 OH Vitamin D TOTAL Assay 25-hydroxyvitamin D: from bone and mineral to general health marker FOR OUTSIDE THE US AND CANADA ONLY Vitamin D Receptors Brain Heart Breast Colon Pancreas Prostate

More information

GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working

GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National

More information

10. Treatment of peritoneal dialysis associated fungal peritonitis

10. Treatment of peritoneal dialysis associated fungal peritonitis 10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of

More information

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea

More information

Atherosclerosis of the aorta. Artur Evangelista

Atherosclerosis of the aorta. Artur Evangelista Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis

More information

Diabetic Nephropathy

Diabetic Nephropathy Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal

More information

Organization and Structure of a Peritoneal Dialysis Program: an important ingredient for success

Organization and Structure of a Peritoneal Dialysis Program: an important ingredient for success Organization and Structure of a Peritoneal Dialysis Program: an important ingredient for success Fredric O. Finkelstein Hospital of St. Raphael, Yale University New Haven. CT 1 Overview of Presentation

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and

More information

It has been reported that increased peritoneal transport

It has been reported that increased peritoneal transport Peritoneal Dialysis International, Vol. 20, pp. 541 547 Printed in Canada. All rights reserved. 0896-8608/00 $3.00 +.00 Copyright 2000 International Society for Peritoneal Dialysis PERITONEAL TRANSPORT

More information

Prognostic impact of uric acid in patients with stable coronary artery disease

Prognostic impact of uric acid in patients with stable coronary artery disease Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,

More information

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

HYPERTENSION ASSOCIATED WITH RENAL DISEASES RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension

Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension Ideal risk prognosticator Easy to acquire Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension Safe -- Non-invasive Robust Gerhard-Paul Diller Astrid Lammers Division of Adult Congenital

More information

Diabetes and the Kidneys

Diabetes and the Kidneys Diabetes and the Kidneys Aim(s) and objective(s) This guideline focuses on the detection, prevention, and management of kidney disease in people with diabetes. The management of end-stage renal disease

More information

Appendix: Description of the DIETRON model

Appendix: Description of the DIETRON model Appendix: Description of the DIETRON model Much of the description of the DIETRON model that appears in this appendix is taken from an earlier publication outlining the development of the model (Scarborough

More information

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Can Common Blood Pressure Medications Cause Diabetes?

Can Common Blood Pressure Medications Cause Diabetes? Can Common Blood Pressure Medications Cause Diabetes? By Nieske Zabriskie, ND High blood pressure, or hypertension, is a major risk factor for cardiovascular disease. In the United States, approximately

More information

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR

More information

Definition, Prevalence, Pathophysiology and Complications of CKD. JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013

Definition, Prevalence, Pathophysiology and Complications of CKD. JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013 Definition, Prevalence, Pathophysiology and Complications of CKD JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013 KI supplements January 2013 Objectives of the course on CKD:

More information

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 84 Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Summary Overview Clinical

More information

Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한

Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한 Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한 Introduction CKD의 정의와 egfr의 측정 CKD의 risk factor와 mechanism 한국의 CKD prevalence 와 prognosis CKD의 치료와

More information

Update in Contrast Induced Nephropathy

Update in Contrast Induced Nephropathy Update in Contrast Induced Nephropathy Yves Pirson Service de Néphrologie, Clin. Univ. St-Luc - UCL A 76-year-old man with - type 2 diabetes - CKD (ser. creat.: 1.8 mg/dl; GFR: 32) presents with angina

More information

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent

More information

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1

More information

HYPERCHOLESTEROLAEMIA STATIN AND BEYOND

HYPERCHOLESTEROLAEMIA STATIN AND BEYOND HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause

More information

Dose-Response Effects of Sodium Intake on Blood Pressure

Dose-Response Effects of Sodium Intake on Blood Pressure I Dose-Response Effects of Sodium Intake on 1 +2 NS +1 NS -2 NS +5 NS 0.46 (20) 4.6 () 25.9 (1128) FIGURE I-1 Blood pressure (mm Hg) according to dietary sodium intake in g/d (mmol/d) among 8 normotensive

More information

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering

More information

Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD

Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD Chronic Kidney Disease and the Electronic Health Record Duaine Murphree, MD Sarah M. Thelen, MD Definition of Chronic Kidney Disease (CKD) Defined by the National Kidney Foundation Either a decline in

More information

GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*

GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* 71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the

More information

Models of Chronic Kidney Disease Care and Initiation of Dialysis. Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK

Models of Chronic Kidney Disease Care and Initiation of Dialysis. Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK Models of Chronic Kidney Disease Care and Initiation of Dialysis Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK Early Crash Landings Talk Outline Pathways & Definitions Guideline recommendations

More information

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9 Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer

More information

INTRODUCTION TO EECP THERAPY

INTRODUCTION TO EECP THERAPY INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

Renovascular Hypertension

Renovascular Hypertension Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension

More information

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT

More information

Spurious systolic hypertension 143

Spurious systolic hypertension 143 Spurious systolic hypertension in youth Michael F O Rourke a, Charalambos Vlachopoulos a and Robert M Graham b Abstract: Six young men diagnosed with systolic hypertension had normal carotid pressure wave

More information

Drug Treatment in Type 2 Diabetes with Hypertension

Drug Treatment in Type 2 Diabetes with Hypertension Hypertension is 1.5 2 times more prevalent in Type 2 diabetes (prevalence up to 80 % in diabetic subjects). This exacerbates the risk of cardiovascular disease by ~ two-fold. Drug therapy reduces the risk

More information

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.

More information

Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction

Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction Esther Lopez Garcia, Matthias B Schulze, Teresa T Fung, James B Meigs, Nader Rifai, JoAnn

More information

Acute on Chronic Liver Failure: Current Concepts. Disclosures

Acute on Chronic Liver Failure: Current Concepts. Disclosures Acute on Chronic Liver Failure: Current Concepts Vandana Khungar, MD MSc Assistant Professor of Medicine University of Pennsylvania, Perelman School of Medicine September 20, 2015 None to declare Disclosures

More information

Assessment of Dietary Management of Patient during Dialysis

Assessment of Dietary Management of Patient during Dialysis Assessment of Dietary Management of Patient during Dialysis Shadia Mohamed 1, Amani Lafe Abdullah 2 1,2 University of Hail, Saudi Arabia Abstract: Inadequate dietary intake is a major determinant of malnutrition

More information

Blood Glucose Levels in Peritoneal Dialysis Are Better Reflected by HbA1c Than by Glycated Albumin

Blood Glucose Levels in Peritoneal Dialysis Are Better Reflected by HbA1c Than by Glycated Albumin Advances in Peritoneal Dialysis, Vol. 30, 2014 Yusuke Watanabe, Yoichi Ohno, Tsutomu Inoue, Hiroshi Takane, Hirokazu Okada, Hiromichi Suzuki Blood Glucose Levels in Peritoneal Dialysis Are Better Reflected

More information

Small artery tone under control of the endothelium

Small artery tone under control of the endothelium Small artery tone under control of the endothelium On the importance of EDHF and myogenic tone in organ (dys)function Simone K. Gschwend Publication of this thesis was supported by generous contributions

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2016 PQRS OPTIONS F INDIVIDUAL MEASURES:

More information

Ischemia and Infarction

Ischemia and Infarction Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Ischemia and Infarction HST.035 Spring 2003 In the US: ~50% of deaths are due to

More information

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years

More information

Mechanism for Dehydration Associated Kidney Disease

Mechanism for Dehydration Associated Kidney Disease Mechanism for Dehydration Associated Kidney Disease Richard J Johnson, University of Colorado A sugarcane worker dying from kidney failure Dr Johnson has received funding from Danone Research Chronic Kidney

More information

Continuous Renal Replacement Therapy. Jai Radhakrishnan, MD, MS

Continuous Renal Replacement Therapy. Jai Radhakrishnan, MD, MS Continuous Renal Replacement Therapy Jai Radhakrishnan, MD, MS History of the CRRT program 1988 Open heart program Active transplant program Deep dissatisfaction with peritoneal dialysis in hemodynamically

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

Patients with end-stage renal disease (ESRD) are at high

Patients with end-stage renal disease (ESRD) are at high Long-Term Outcome of Renal Transplant Recipients in the United States After Coronary Revascularization Procedures Charles A. Herzog, MD; Jennie Z. Ma, PhD; Allan J. Collins, MD Background Retrospective

More information

Renal Blood Flow GFR. Glomerulus Fluid Flow and Forces. Renal Blood Flow (cont d)

Renal Blood Flow GFR. Glomerulus Fluid Flow and Forces. Renal Blood Flow (cont d) GFR Glomerular filtration rate: about 120 ml /minute (180 L a day) Decreases with age (about 10 ml/min for each decade over 40) GFR = Sum of the filtration of two million glomeruli Each glomerulus probably

More information

David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010

David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes

More information

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS

More information

20/03/2013. What is it and how did it disappear? What is it and how did it not disappear?

20/03/2013. What is it and how did it disappear? What is it and how did it not disappear? Calcium, phosphor and magnesium: pathophysiology, diagnosis, clinical management S. Van Laecke Ghent University Hospital BVN Core Curriculum Course 2013 What is it and how did it disappear? Miyamoto M

More information

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

Objectives. Functions of the kidney. Renal failure. Categories of AKI. Acute Kidney Injury (AKI) RENAL FAILURE: AN UPDATE FOR HEALTHCARE PROFESSIONALS

Objectives. Functions of the kidney. Renal failure. Categories of AKI. Acute Kidney Injury (AKI) RENAL FAILURE: AN UPDATE FOR HEALTHCARE PROFESSIONALS RENAL FAILURE: AN UPDATE FOR HEALTHCARE PROFESSIONALS Tamara Kear, PhD, RN Assistant Professor of Nursing Villanova University Objectives Review normal kidney function. Define the pathophysiology of acute

More information

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest

More information

Cardiovascular Risk in Diabetes

Cardiovascular Risk in Diabetes Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,

More information

Summary HTA. HTA-Report Summary. Introduction

Summary HTA. HTA-Report Summary. Introduction Summary HTA HTA-Report Summary Antioxidative vitamines for prevention of cardiovascular disease for patients after renal transplantation and patients with chronic renal failure Schnell-Inderst P, Kossmann

More information

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME 1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome

More information

Vascular System The heart can be thought of 2 separate pumps from the right ventricle, blood is pumped at a low pressure to the lungs and then back

Vascular System The heart can be thought of 2 separate pumps from the right ventricle, blood is pumped at a low pressure to the lungs and then back Vascular System The heart can be thought of 2 separate pumps from the right ventricle, blood is pumped at a low pressure to the lungs and then back to the left atria from the left ventricle, blood is pumped

More information

ESIM 2014 WHEN CHRONIC BECOMES ACUTE

ESIM 2014 WHEN CHRONIC BECOMES ACUTE ESIM 2014 WHEN CHRONIC BECOMES ACUTE Anna Salina, MD Pauls Stradins Clinical University Hospital Riga, Latvia 37 years old female, 50 kg, 150 cm Complaints Severe edema +8 kg Tiredness, dry cough Chills

More information

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital

More information

Will The Coronary Calcium Score Affect the Decision To Treat With Statins?

Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Amresh Raina M.D. Division of Cardiology University of Pennsylvania Disclosures No financial relationships relevant to this presentation

More information

Guidelines for the management of hypertension in patients with diabetes mellitus

Guidelines for the management of hypertension in patients with diabetes mellitus Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes

More information

DIABETES. Eyes, Heart, Nerves, Feet, and Kidneys. www.kidney.org

DIABETES. Eyes, Heart, Nerves, Feet, and Kidneys. www.kidney.org DIABETES Eyes, Heart, Nerves, Feet, and Kidneys www.kidney.org About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries that help

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Monitoring the Hemodialysis Dose

Monitoring the Hemodialysis Dose KDIGO Controversies Conference Novel techniques and innovation in blood purification: How can we improve clinical outcomes in hemodialysis? October 14-15, 2011 Paris France Monitoring the Hemodialysis

More information

Estimated GFR Based on Creatinine and Cystatin C

Estimated GFR Based on Creatinine and Cystatin C Estimated GFR Based on Creatinine and Cystatin C Lesley A Stevens, MD, MS Tufts Medical Center, Tufts University School of Medicine Boston MA Chronic Kidney Disease-Epidemiology Collaboration UO1 DK 053869,

More information

The Newly Developed Calcium Antagonist, Azelnidipine, Increases Drain Volume in Continuous Ambulatory Peritoneal Dialysis Patients

The Newly Developed Calcium Antagonist, Azelnidipine, Increases Drain Volume in Continuous Ambulatory Peritoneal Dialysis Patients Advances in Peritoneal Dialysis, Vol. 22, 2006 Hiromichi Suzuki, Tsutomu Inoue, Kazuhiro Kobayashi, Junko Shoda, Hidetomo Nakamoto Many patients undergoing continuous ambulatory peritoneal dialysis (CAPD)

More information

Interpretation of Laboratory Values

Interpretation of Laboratory Values Interpretation of Laboratory Values Konrad J. Dias PT, DPT, CCS Overview Electrolyte imbalances Renal Function Tests Complete Blood Count Coagulation Profile Fluid imbalance Sodium Electrolyte Imbalances

More information

Perioperative Cardiac Evaluation

Perioperative Cardiac Evaluation Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project

More information

Understanding Treatment Options for Renal Therapy

Understanding Treatment Options for Renal Therapy Understanding Treatment Options for Renal Therapy Kidney failure happens to many different people for many different reasons 1 What causes kidney failure? Diabetes Chronic infection High blood pressure

More information

LIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES

LIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES Test Code Test Name CPT CHOL Cholesterol, Serum 82465 HDL HDL, (High Density Lipoprotein) 83718 TRIG Triglycerides, Serum 84478 FTRIG Triglycerides (Fluid) 84478 LIPID Lipid Panel 80061 LDL LDL (Low Density

More information

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it.

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it. Heart Failure EXERCISES Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it. ) 1. Heart rate increase is a kind of economic compensation, which should

More information

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke

More information

survival, morality, & causes of death Chapter Nine introduction 152 mortality in high- & low-risk patients 154 predictors of mortality 156

survival, morality, & causes of death Chapter Nine introduction 152 mortality in high- & low-risk patients 154 predictors of mortality 156 introduction 152 < mortality in high- & low-risk patients 154 < predictors of mortality 156 < impact of anemia & dialysis therapy on mortality 158 < mortality in esrd patients with rare s 16 < expected

More information

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic

More information

Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration

Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration Hiddo Lambers Heerspink Department of Clinical Pharmacology University Medical

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

Geriatric Cardiology: Challenges and Strategies

Geriatric Cardiology: Challenges and Strategies Geriatric Cardiology: Challenges and Strategies No financial disclosures Geriatrics -- No Specific Age 'you know it when you see it' Functional Status Polypharmacy Impaired Renal Function Diagnostic Testing:

More information

Clinical Performance Goals 2010-2011

Clinical Performance Goals 2010-2011 Clinical Performance Goals 2010-2011 Clinical Performance Goals 2010-2011 Table of Contents Table of Contents... 1 Health Care Quality Improvement Program... 2 Clinical Performance Measures... 6 Chapter

More information

Antiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study

Antiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study Antiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study Titus F. Msoka Supervisors Marceline van Furth Yvo Smulders

More information

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic

More information

Nierfunctiemeting en follow-up van chronisch nierlijden

Nierfunctiemeting en follow-up van chronisch nierlijden Nierfunctiemeting en follow-up van chronisch nierlijden 12 Jan 2016 Patrick Peeters, M.D. Dept Nephrology Ghent University Hospital Plan of presentation 1/ Renal function determination: Measured GFR Estimated

More information

Five things to watch in nephrology. David Sheikh-Hamad, MD Professor of Medicine, Molecular & Cellular Biology Baylor College of Medicine

Five things to watch in nephrology. David Sheikh-Hamad, MD Professor of Medicine, Molecular & Cellular Biology Baylor College of Medicine Five things to watch in nephrology David Sheikh-Hamad, MD Professor of Medicine, Molecular & Cellular Biology Baylor College of Medicine Financial Disclosures David Sheikh-Hamad, MD In the context of my

More information